Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Leivers

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Organic Letters|September 12, 2003
A forbidden rearrangementMartin Leivers, Iris Tam, Kevin Groves, et al.
Journal of Medicinal Chemistry|February 27, 2014
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compoundWieslaw M Kazmierski, Andrew Maynard, Maosheng Duan, et al.
Journal of Medicinal Chemistry|November 15, 2013
Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanismMartin Leivers, John F Miller, Stephanie A Chan, et al.
Journal of Viral Hepatitis|February 26, 2020
Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participantsYanli Deng, Fiona Campbell, Kelong Han, et al.
Clinical Pharmacology in Drug Development|March 13, 2019
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy SubjectsKelong Han, Jennifer Cremer, Robert Elston, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Organic Letters|September 12, 2003
A forbidden rearrangementMartin Leivers, Iris Tam, Kevin Groves, et al.
Journal of Medicinal Chemistry|February 27, 2014
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compoundWieslaw M Kazmierski, Andrew Maynard, Maosheng Duan, et al.
Journal of Medicinal Chemistry|November 15, 2013
Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanismMartin Leivers, John F Miller, Stephanie A Chan, et al.
Journal of Viral Hepatitis|February 26, 2020
Randomized clinical trials towards a single-visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG-101 in chronic hepatitis C patients and long-acting injectable GSK2878175 in healthy participantsYanli Deng, Fiona Campbell, Kelong Han, et al.
Clinical Pharmacology in Drug Development|March 13, 2019
A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy SubjectsKelong Han, Jennifer Cremer, Robert Elston, et al.
Pageof 1